NEWS・COLUMN
We send the latest information from SMC Laboratories.
CytoDyn Reports Significant Fibrosis Reversal in SMC Lab Studies
In a great collaboration with CytoDyn Inc., we are pleased to share promising preclinical results demonstratin…
A New Approach to Pulmonary Fibrosis Research: Introducing SMC Laboratories’ IPF Model
SMC Laboratories, Inc. (Tokyo, Japan) is a preclinical CRO specializing in pharmacological evaluations using d…
Chitinase-1 Inhibition Attenuates MASH Progression: A Novel Therapeutic Approach via Metabolic Reprogramming
In May 2025, a collaborative research team from OncoArendi Therapeutics and academic institutions in Poland pu…
Case study: Study published in Periodontitis promotes hepatocellular carcinoma Stelic Animal model mice.
We introduce a case study of basic research using our MASH model (STAM™ model). It has been reported th…
CytoDyn has published a press release regarding the leronlimab efficacy preclinical study for MASH/fibrosis provided by SMC
CytoDyn Inc., which is our client, has announced the results of pharmacology study using a STAM™ mouse model. …
Case study: Study published in Clinical and Translational Science on the effects of adiponectin-derived peptide ALY688 in MASH/liver fibrosis of STAM model.
We introduce a case study of pharmacology study of adiponectin-derived peptide ALY688 using our MASH model (ST…
Our clients’ presentations at AASLD ~The Liver Meeting 2024 ~
Our clients presented data on treatment of MASH using STAMTM model at the AASLD ~The Liver Metting 2024~ (Nove…
Case study: Study published in Nature Biotechnology on the effects of TNIK inhibitor in lung and kidney fibrosis models.
We want to introduce a paper by Insilico Medicine, a company that focuses on fibrosis to develop drugs, and af…
Preclinical HCC study with positive control, Lenvatinib
We recently obtained new evaluation data on the Lenvatinib in our STAM model and it shows significantly improv…
Enhance Research with Our Updated Model Lineup
We are introducing new disease models to our portfolio of preclinical mouse models. Our extensive lineup offer…
Results of Resmetirom fibrosis targeting study using STAM™ model
Recently, we have obtained the results of a study of resmetirom for the treatment of fibrosis using STAMTM-HCC…
MOA demonstration #4 【Gut-Liver Axis】｜Evaluation of the efficacy of a compound in the treatment of MASH via the Gut-Liver Axis using STAM™ mice
Today, we introduce the pre-clinical studies in MASH drug development targeting Gut-Liver axis. In MASH…